Corcept Therapeutics shared its third-quarter results, showing sales of $340.5 million, up 33% from last quarter.

Nov 3, 2026, 7:20 PM ETResultsRead the original at Benzinga

Good for CORT

Corcept reported $340.5 million in Q3 sales, up 33% from the prior quarter, and $126.8 million in profit. It kept its 2026 sales forecast; future Lithioli growth and a pending FDA decision remain uncertain, but current results favor the company.

CORT · Corcept Therapeutics

AI read · Good for CORT

The AI's read

More sales from Korlym and Lithioli give Corcept a larger base for the year. The company also has more cash to fund its work and kept its 2026 sales forecast. A December FDA decision on relacorilant is still pending, and hoped-for Lithioli growth has not happened yet. Those future outcomes could disappoint, but they do not erase the sales and profit already reported.

Get alerts for CORT

Follow Corcept Therapeutics (CORT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CORT

Free on the App Store and Google Play, or on the web.